Article
Public, Environmental & Occupational Health
Tercia Moreira Ribeiro Da Silva, Ana Carolina Micheletti Gomide Nogueira de Sa, Mark Anthony Beinner, Mery Natali Silva Abreu, Fernanda Penido Matozinhos, Ana Paula Sayuri Sato, Ed Wilson Rodrigues Vieira
Summary: The objective of this study was to analyze the number of HPV vaccine doses administered before and after social distancing measures in response to the COVID-19 pandemic in different states and regions of Brazil. The results showed a significant reduction in the number of administered HPV vaccine doses during the pandemic, but there was an increase in the doses administered during the period of social distancing.
INTERNATIONAL JOURNAL OF PUBLIC HEALTH
(2022)
Article
Biotechnology & Applied Microbiology
Trevor Christensen, Sherri Zorn, Kathy Bay, Katherine Treend, Chrystal Averette, Nicole Rhodes
Summary: Although the Advisory Committee on Immunization Practices recommends routine HPV vaccination at age 11-12, the vaccination rates for HPV are lower compared to Tetanus-diphtheria-pertussis (Tdap) and Meningococcal conjugate (MenACWY). Research suggests that children who start HPV vaccination at age 9 are more likely to complete the series on time. Washington state implemented a provider reminder through its immunization information system (WAIIS) to increase HPV vaccine initiation at 9 years old.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Jennifer Isher-Witt, Shaylen Foley, Anna Hassan, Amelia Sloan, Jennifer Nkonga, Marcie Fisher-Borne
Summary: The American Cancer Society collaborated with healthcare partners to implement quality improvement interventions to improve HPV vaccination rates among adolescents. Data from the project years showed significant increases in initiation rates for ages 9-10, while rates for ages 11-12 and 13 remained relatively stable. In 2022, significant increases in initiation rates were observed across all ages.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Tamera Coyne-Beasley, Rebecca R. Ortiz
Summary: Many U.S. adolescents don't complete the HPV vaccine series until late adolescence, increasing their vulnerability to future HPV infection and cancers. Shifting the routine recommendation to start the vaccine series at age nine instead of 11-12 can improve vaccination rates and reduce health disparities. This article discusses the challenges, opportunities, and communication strategies for this recommendation, while considering social determinants of health.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Sonja C. O'Leary, Holly M. Frost
Summary: Vaccinating against HPV at 9 years of age can effectively improve vaccine initiation and completion rates by age 13. A study showed that the percentage of patients receiving at least 1 dose of HPV vaccine increased from 30% to 43% post-intervention, while the percentage receiving 2 doses increased from 19.3% to 42.7%. The overall initiation rate of HPV vaccination by age 13 increased from 42% to 54%, with completion rates also showing improvement.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Heather M. Brandt, Alison Footman, Prajakta Adsul, Shoba Ramanadhan, Deanna Kepka
Summary: Starting HPV vaccination at age 9 is effective in preventing HPV cancer and pre-cancer. However, HPV coverage rates are low. The American Academy of Pediatrics and the American Cancer Society endorse starting HPV vaccination at age 9.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Infectious Diseases
Cornelia Waehner, Johannes Huebner, Doerte Meisel, Joerg Schelling, Rebecca Zingel, Sarah Mihm, Regine Woelle, Miriam Reuschenbach
Summary: This study aimed to describe the uptake of HPV vaccination in boys during the COVID-19 pandemic in Germany. The study found that four months after the introduction of mandatory reimbursement, the number of first doses in boys was comparable to that in girls. However, compared to the same month in 2019, the number of first doses declined by 49% (girls) in 2020 and 71% (boys) in 2021. At the end of 2021, the vaccination rate for 15-year-old boys (2006 birth cohort) reached 44.4% (initiated series) and 26.4% (completed series).
Article
Biotechnology & Applied Microbiology
Shaylen Foley, Jennifer Nkonga, Marcie Fisher-Borne
Summary: Health plans can influence providers and patients to understand and increase HPV vaccination coverage. Initiating vaccination at age nine lays the groundwork for on-time HPV cancer prevention by age 13.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Maude Dionne, Chantal Sauvageau, Marilou Kiely, Mika Rathwell, Thilina Bandara, Cory Neudorf, Eve Dube
Summary: This study describes the barriers and enabling conditions of HPV vaccination in school programs and identifies potential solutions to improve vaccine uptake rates and acceptance.
Editorial Material
Rheumatology
Ines Colmegna, Michael Libman
Summary: Regarding vaccination in individuals with rheumatic and musculoskeletal diseases, the limited evidence available is supplemented by a new guideline that follows a rigorous methodology, offering valuable guidance to healthcare professionals and patients. The majority of recommendations are conditional, emphasizing the need for more research.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Kunal Saxena, Niranjan Kathe, Poorva Sardana, Lixia Yao, Ya-Ting Chen, Noel T. Brewer
Summary: The US Advisory Committee on Immunization Practice recommends routine HPV vaccination starting at 11-12 years, but states that it can be initiated as early as 9 years. A study found that initiating HPV vaccination at 9-10 years of age was associated with a higher rate of series completion by 13 years of age compared to initiating at 11-12 years of age. Factors such as provider type, health care plan, sex, race/ethnicity, and wellness checks or non-HPV vaccinations were associated with series completion by 13 years of age.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Medicine, General & Internal
Anne E. Berset, Mary Carol Burkhardt, Yingying Xu, Anne Mescher, William B. Brinkman
Summary: Outreach messages delivered via electronic health record patient portals increased the rates of scheduling and completing well child care visits and receiving COVID-19 vaccine.
Review
Immunology
Fernando E. Diaz, Lourdes Arruvito, Jorge Geffner
Summary: The SARS-CoV-2 pandemic has caused a significant number of deaths worldwide and has prompted reflection on the inequity in vaccine access, calling for joint efforts in vaccine production and reconsideration of intellectual property rights.
CURRENT OPINION IN IMMUNOLOGY
(2023)
Article
Immunology
Eric P. F. Chow, Christopher K. Fairley, Huachun Zou, Rebecca Wigan, Suzanne M. Garland, Alyssa M. Cornall, Steph Atchison, Sepehr N. Tabrizi, Marcus Y. Chen
Summary: Antibody levels following vaccination against HPV are substantially higher in adolescent gay and bisexual men compared to those with natural infection. This study provides evidence that HPV vaccination can effectively boost immunity in this population, with antibody levels remaining stable over time.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Biotechnology & Applied Microbiology
Erika L. Thompson, Ellen M. Daley, Tricia Washburn, Kim Salisbury-Keith, Debbie Saslow, Holly B. Fontenot, Gregory D. Zimet
Summary: HPV vaccination can prevent multiple cancers, but the vaccination rates in the United States are low. Implementing school-entry requirements may be an effective policy approach to improve vaccination rates.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)